Binance liquidated a single Bitcoin short position worth $2.56 million on its perpetual futures market at a price of $86,567. This liquidation occurred on October 4 at 6:16 p.m. ET and involved closing a short trade, which profits from price declines, once it hit the specified threshold. The data comes from Binance's public liquidation records but does not specify the cause behind the liquidation. This event highlights the volatility and risk in Bitcoin futures trading.
The recent Binance liquidation of a $2.56 million Bitcoin short position provides context for cryptocurrency market activity. For readers following crypto markets, here is Pluang's snapshot as of Oct 05, 2026 05:02 WIB: out of 50 major cryptocurrencies priced on Pluang, 32 rose and 16 fell. Notable movers include ATOM at Rp31.288 with a 1-day change of +2.89% and Pluang order activity of 20% Sell / 80% Buy, COMP at Rp443.257 with -2.80% and 0% Sell / 100% Buy, and CRV at Rp6.665 with -2.36% and 2% Sell / 98% Buy.
Bitcoin's price increased by 0.59% within an hour on October 5, moving from $86,052 to $86,564. During this period, $13.96 million in short positions were liquidated across Binance, Bybit, and OKX, while only $10,000 in long positions were liquidated...
France's Schneider Electric is close to acquiring US software company PTC for about $20 billion, according to the Financial Times. The deal could be announced as soon as Monday, though discussions are still ongoing and not guaranteed. PTC, based in B...
This week in crypto was volatile with Bitcoin briefly surpassing $87k before dropping below $84k. Citi raised its 12-month Bitcoin price target to $113k, signaling bullish sentiment. Among altcoins, Midnight (NIGHT) surged 85%, showing strong accumul...
Oracle has committed $10 million and formed a strategic partnership to support the Nashville Symphony as it restructures. This investment will help the orchestra address its immediate financial challenges, resume its 2026-27 season, and bring back fu...
CSL and Alentis Therapeutics have formed an exclusive global partnership to co-develop and co-promote lixudebart, a novel therapy targeting claudin-1 for kidney and liver diseases. CSL will pay Alentis $355 million upfront and up to $1.2 billion in m...
